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Meningeal melanocytomas are extremely rare tu-mors originating from leptomeningeal melano-cytes. The first reported description, in the early 
1970s, was by Limas and Tio.10 Although little is known 
about this tumor entity as only a few case reports have 
been published over the past few decades, the tumors 
mostly occur along the spine and the posterior fossa with a 
peak incidence around the 5th decade and a slight female 
predominance.3,11
According to the classification suggested by Brat et al.,2 
melanocytic neoplasms are categorized histologically as 
melanocytomas, melanocytomas of intermediate grade, or 
melanomas exhibiting typical malignant features such as 
necrosis and high mitotic activity. Recent in-depth molec-
ular characterization of melanocytomas revealed distinct 
mutational and chromosomal fingerprints separating me-
lanocytomas from other melanotic tumors such as mela-
noma metastases or melanotic schwannomas.6
Treatment aims at the complete surgical removal of the 
tumor and postoperative adjuvant radiotherapy.
case report
A 58-year-old woman presented with a history of pro-
gressive ataxia, progressive urinary and bowel inconti-
nence, and weight loss of 6 kg over a period of 6–8 weeks. 
Neurological examination revealed a paraparesis of the 
lower extremities (M0/5 muscle strength grade of the right 
leg; M1–2/5, left leg) with paresthesia and hypesthesia 
starting from the T-10 dermatome downward.
Her medical history included breast cancer diagnosed 
in 2008, which was treated with a lumpectomy, adjuvant 
chemotherapy (6 cycles of Taxotere, Adriamycin, and cy-
clophosphamide), and postoperative whole breast radio-
therapy (including supraclavicular lymph nodes) with a 
total dose of 50.4 Gy and followed by a 16-Gy boost to 
the tumor bed.
Upon admission, MRI of the spine revealed a 3.7-cm 
isodense/slightly hyperintense intramedullary lesion at 
T9–10. After administration of gadolinium, the lesion 
appeared hyperintense on T1-weighted images (Fig. 1A). 
T2-weighted images showed a myelopathy signal from T-7 
to T-12. The differential diagnosis included ependymoma, 
astrocytoma, and intraspinal metastasis.
The patient thus underwent a laminectomy at the T9–10 
levels and a complete microsurgical resection of the in-
tramedullary tumor under continuous neuromonitoring. 
The lesion was grayish-red and heavily vascularized with 
a macroscopic appearance that closely resembled an epen-
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dymoma. A postoperative MRI scan showed no residual 
contrast-enhancing mass (Fig. 1B).
Histopathological workup showed a highly cellular tu-
mor composed of epithelioid-shaped tumor cells with a 
scant to moderate cytoplasmic pigmentation and vesicular 
nuclei with prominent nucleoli (Fig. 2A). Single mitotic 
figures and small necrotic areas were present. The prolif-
eration index Ki 67 (MIB1) focally reached 10% (Fig. 2B). 
Tumor cells strongly expressed S100 and HMB45 (Fig. 2C 
and D), but were negative for BRAF V600E (VE1), pan-cy-
tokeratin (AE1/3), EMA, and GFAP. Therefore, the tumor 
was classified as a melanoma of unknown primary (MUP).
However, neither dermatological and ophthalmological 
examinations nor imaging studies including CT from the 
neck to the pelvis and cerebral MRI revealed a primary 
tumor site. Based on the diagnosis of an MUP, the inter-
disciplinary tumor board recommended postoperative ra-
diotherapy of T8–11 with 50 Gy in 25 fractions of 2.0 Gy 
followed by 4 cycles of ipilimumab.
One week prior to completion of radiotherapy, compre-
hensive molecular analyses of 6 key genes (BRAF, NRAS, 
cKIT, TERT promoter, GNA11, and GNAQ) revealed a 
hotspot missense mutation in codon 209 of the GNAQ 
gene (Fig. 3) while all other genes were not mutated 
(wild type). GNAQ mutations were previously found to be 
linked to uveal melanomas and melanocytomas,18 which 
can hardly be discriminated by histology alone. However, 
as ophthalmological consultation had already ruled out 
the presence of a uveal melanoma, the diagnosis of mela-
nocytoma of intermediate grade was favored over MUP. 
Adjuvant treatment with ipilimumab was therefore omit-
ted, and the radiation therapy was completed.
Radiotherapy was well tolerated by the patient, and 
the paraparesis improved only on the left side. At the end 
of radiotherapy, the patient could freely move her left leg 
(M3/5), while the right leg remained paralyzed (M0/5). 
The lower-limb paresthesia and hypesthesia, as well as the 
urinary and bowel incontinence, did not improve. At the 
first follow-up 3 months after the initial diagnosis, she pre-
sented with a persistent M3/5 of the left leg and a mildly 
increased strength grade (M1/5) of the right leg. Although 
the paresthesia had not improved, the patient regained 
bladder and bowel control. MRI of the total spine did not 
detect any remaining tumor (Fig. 1C) and a whole-body 
MRI scan showed no further lesions. After discharge, the 
patient was scheduled for quarterly follow-up visits in-
cluding MRI of the total spine.
discussion
Melanocytomas, especially of intermediate grade, and 
melanomas share a variety of histological features and 
therefore may be challenging for pathologists. Brat and 
colleagues2 described low-grade melanocytomas as well-
differentiated lesions with tight nests, vasocentric fas-
cicles, or sheet-like arrangements that typically lack ma-
lignant histological features such as high mitotic activity, 
necrosis, and nuclear pleomorphism (Fig. 2). Prominent 
nucleoli are a common feature of meningeal melanocyto-
mas.16 Melanomas, however, consist of spindled or epithe-
lioid cells with arrangements similar to those of melano-
cytomas, are densely cellular, and show significant cellular 
pleomorphism and nuclear atypia. Intermediate-grade me-
lanocytomas, show histological features of aggressive be-
havior (necrosis, hypercellularity, mitosis, invasion of CNS 
structures) but lack the cellular atypia present in malignant 
melanomas.8
Immunohistochemically, both melanomas and menin-
geal melanocytomas are characterized by a positive stain-
ing for anti–melanoma antibody (HMB-45), S100 protein, 
and a negative reaction to EMA.16
Molecular analyses played a key role in establishing the 
more precise diagnosis for our patient. Without the detec-
tion of GNAQ mutation, our patient would have been mis-
diagnosed as having a malignant melanoma. In addition to 
uveal melanomas, blue nevi, and leptomeningeal or uveal 
melanocytomas, the GNAQ mutation may be found only in 
melanomas that developed from these benign precursors.6 
Thus, in the absence of these lesions a GNAQ mutation is 
almost pathognomonic for melanocytoma. The GNAQ (G 
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and encodes for a GTP-binding protein within the MAP 
kinase pathway.17 GNAQ codon 209 mutations (as detected 
in our patient) are found in pituitary and thyroid tumors, 
blue nevi, and ocular melanomas.9,12 The mutation results 
in constitutive activation of the protein, which permanently 
activates the MAP kinase pathway similar to BRAF and 
NRAS mutations.14 Küsters-Vandevelde et al.7 suggested 
that the presence of a GNAQ mutation and the absence of 
typical mutations of cutaneous melanomas such as BRAF 
or NRAS in a melanocytic neoplasm of the CNS strongly 
indicate a primary CNS tumor. On the other hand, the pres-
ence of a BRAF and NRAS mutation in the absence of a 
GNAQ mutation points to a primary cutaneous melanoma.
The symptoms of melanocytomas depend on the an-
atomical site. The majority of patients will present with 
neurological symptoms caused by edema and compres-
sion of nerve bundles or brain tissue. In our case, spinal 
cord compression caused paraparesis, which partly re-
solved after combined treatment with surgery and radio-
therapy. Different approaches to treatment were analyzed 
in a study by Rades et al.15 who showed that the 5-year 
survival rates were 100% for complete resection with or 
without adjuvant radiation. Incomplete resection with ad-
juvant radiation also achieved 100% 5-year survival rates, 
whereas an incomplete resection alone only achieved 46% 
5-year survival rates. Therefore, the current gold stan-
dard of treatment for intracranial or intraspinal melano-
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the small number of cases, the role of adjuvant radiation 
therapy after complete resection is almost impossible to 
evaluate. Thus, in our opinion, radiotherapy should not be 
omitted for 2 reasons. First, although imaging techniques 
may have significantly improved and detection of residual 
tumor volume is more feasible nowadays, the definition 
of complete resection of a CNS tumor remains controver-
sial in the absence of the possibility to assess a resection 
margin. Second, malignant transformation is possible,4,13 
and metastasizing meningeal melanocytomas1,5 have been 
reported in the literature.
Our patient was treated with a radiotherapy regimen of 
25 fractions of 2.0 Gy, which was chosen at a time where 
the underlying tumor was believed to be a malignant 
melanoma. We have not observed radiotherapy-related ad-
verse events so far, and, as Rades et al.15 hypothesized an 
improved local control with doses exceeding 40 Gy, we 
suggest that the “melanoma regimen” is a safe and practi-
cal approach for spinal meningeal melanocytoma.
Although this regimen appears to achieve high local 
control rates, we have initially scheduled the patient for 
quarterly follow-up visits as there is, in our opinion, not 
enough long-term data on these tumors available that 
would justify longer follow-up intervals.
In conclusion, we report on how molecular analyses 
helped establish the diagnosis of a meningeal melanocy-
toma of intermediate grade. In the absence of histologi-
cally confirmed (extra)cutaneous primary melanomas, we 
suggest a routine mutational analysis in the genetic loci of 
GNAQ (as well as BRAF, NRAS, cKIT, and GNA11) in all 
cases of melanocytic neoplasms of the CNS.
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